Global, regional, and national epidemiology of childhood neuroblastoma (1990-2021): a statistical analysis of incidence, mortality, and DALYs.

Jusen Nong, Cheng Su, Changhua Li, Congjun Wang, Wei Li, Yong Li, Peng Chen, Yanqiang Li, Zihao Li, Xinjin She, Zuxin Yuan, Sentian Liu, Chao Chen, Qian Liao, Yige Luo, Bo Shi
Author Information
  1. Jusen Nong: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  2. Cheng Su: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  3. Changhua Li: Department of Emergency, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  4. Congjun Wang: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  5. Wei Li: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  6. Yong Li: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  7. Peng Chen: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  8. Yanqiang Li: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  9. Zihao Li: Department of Thoracic Surgery, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi Zhuang Autonomous Region, PR China.
  10. Xinjin She: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  11. Zuxin Yuan: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  12. Sentian Liu: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  13. Chao Chen: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  14. Qian Liao: Department of Epidemiology and Biostatistics, School of Public Health, Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  15. Yige Luo: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.
  16. Bo Shi: Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Autonomous Region, PR China.

Abstract

Background: Neuroblastoma is the most prevalent extracranial solid tumor in pediatric populations worldwide, representing 8-10% of childhood malignancies and contributing to approximately 15% of pediatric cancer-related fatalities. This study aims to report global trends in the incidence, mortality, and disability-adjusted life years (DALYs) of childhood neuroblastoma from 1990 to 2021.
Methods: The study utilized data from the Global Burden of Disease (GBD) database to analyze neuroblastoma incidence, mortality, and DALYs in children aged 0-14 years. Rates for incidence, mortality, and DALYs were calculated per 100,000 population, with 95% uncertainty intervals (UIs). Data from 204 countries and territories were stratified by age, sex, and location. Trends were assessed using Joinpoint regression models to compute the annual percent change (APC) and log-transformed linear regression models to calculate the estimated average annual percentage change (EAPC).
Findings: Globally, the incidence of neuroblastoma in children in 2021 was 5560 cases (95% UI, 3734.21-7560.03), with 1977 deaths (95% UI, 1445.04-2528.54), and 174,186.30 DALYs (95% UI, 127,104.64-223,265.92). From 1990 to 2021, the incidence increased by 30.26% (95% UI, -1.24% to 72.51%), mortality by 20.35% (95% UI, -12.44% to 63.30%), and DALYs by 20.08% (95% UI, -12.89% to 63.27%). The incidence rate rose from 0.25 (95% UI, 0.18-0.33) per 100,000 individuals in 1990 to 0.28 (95% UI, 0.19-0.38) per 100,000 individuals in 2021, an overall increase of 12.60% (95% UI, -14.62% to 49.12%). Among the five Sociodemographic Index (SDI) regions, the highest EAPCs were observed in the low-to-mid SDI regions for incidence (1.87%; 95% CI, 1.64%-2.10%), mortality (1.22%; 95% CI, 1.09%-1.34%), and DALYs (1.36%; 95% CI, 1.15%-1.57%). Regionally, Central Asia exhibited the fastest annual increase in incidence (EAPC = 2.76%; 95% CI, 2.18%-3.34%). At the national level, India had the highest number of neuroblastoma cases globally in 2021, with 685 cases (95% UI, 404.16-1007.67).
Interpretation: The global trends for incidence, mortality, and DALYs related to pediatric neuroblastoma initially increased and then decreased, although an overall increasing trend was observed. However, the burden of disease remains significant in low-, low-middle-, and middle-SDI regions. A comprehensive understanding of the epidemiology of neuroblastoma in children is crucial for enhancing disease prevention and control efforts.
Funding: This research was funded by the Guangxi Natural Science Foundation (Grant No. 2024GXNSFAA010420) and the Youth Science Foundation of Guangxi Medical University (Grant No. GXMUYSF202404).

Keywords

References

  1. Lancet Oncol. 2018 Dec;19(12):1617-1629 [PMID: 30442501]
  2. Lancet. 2024 May 18;403(10440):2100-2132 [PMID: 38582094]
  3. Oncogene. 2018 Mar;37(11):1417-1429 [PMID: 29321660]
  4. Oncogene. 2005 May 5;24(20):3377-84 [PMID: 15735707]
  5. Nat Genet. 2021 May;53(5):683-693 [PMID: 33767450]
  6. J Clin Oncol. 2010 May 20;28(15):2625-34 [PMID: 20404250]
  7. Lancet Oncol. 2013 Mar;14(3):e95-e103 [PMID: 23434338]
  8. Lancet Oncol. 2024 Jul;25(7):922-932 [PMID: 38936379]
  9. Lancet. 2024 May 18;403(10440):2133-2161 [PMID: 38642570]
  10. Lancet. 2007 Jun 23;369(9579):2106-20 [PMID: 17586306]
  11. Nat Genet. 2023 Apr;55(4):619-630 [PMID: 36973454]
  12. Cell Tissue Res. 2018 May;372(2):211-221 [PMID: 29445860]
  13. Nat Rev Clin Oncol. 2022 Aug;19(8):515-533 [PMID: 35614230]
  14. Genes Chromosomes Cancer. 2024 Jul;63(7):e23260 [PMID: 39031441]
  15. J Exp Clin Cancer Res. 2022 Mar 11;41(1):92 [PMID: 35277192]
  16. World J Surg Oncol. 2023 Apr 12;21(1):130 [PMID: 37046344]
  17. Lancet. 2007 Oct 20;370(9596):1453-7 [PMID: 18064739]
  18. Stat Med. 2000 Feb 15;19(3):335-51 [PMID: 10649300]
  19. Lancet Oncol. 2003 Aug;4(8):472-80 [PMID: 12901961]
  20. J Clin Oncol. 2015 Sep 20;33(27):3008-17 [PMID: 26304901]
  21. JAMA Oncol. 2022 Mar 01;8(3):420-444 [PMID: 34967848]
  22. Cancer Sci. 2024 May;115(5):1634-1645 [PMID: 38411285]
  23. Lancet. 2020 Oct 17;396(10258):1285-1306 [PMID: 32679112]
  24. JAMA Pediatr. 2022 Aug 1;176(8):787-796 [PMID: 35639401]
  25. Int J Cancer. 1992 Oct 21;52(4):538-43 [PMID: 1399133]
  26. JCI Insight. 2023 Nov 22;8(22): [PMID: 37991019]
  27. Lancet Oncol. 2014 Jan;15(1):35-47 [PMID: 24314616]
  28. Biol Sex Differ. 2020 Apr 15;11(1):17 [PMID: 32295632]
  29. N Engl J Med. 1999 Oct 14;341(16):1165-73 [PMID: 10519894]
  30. Exp Cell Res. 2018 Sep 15;370(2):671-679 [PMID: 30036539]
  31. Cancer. 2024 Jan 1;130(1):117-127 [PMID: 37755665]
  32. Ann Surg Oncol. 2023 Apr;30(4):2087-2093 [PMID: 36539579]

Word Cloud

Created with Highcharts 10.0.095%incidenceUIDALYsmortalityneuroblastoma120210CIpediatricchildhoodstudy1990Globalchildrenper100000annualcasesregionsdiseaseNeuroblastomaglobaltrendsyearsregressionmodelschange30increased20 -1263individualsoverallincreaseSDIhighestobserved34%nationalburdenepidemiologyGuangxiScienceFoundationGrantBackground:prevalentextracranialsolidtumorpopulationsworldwiderepresenting8-10%malignanciescontributingapproximately15%cancer-relatedfatalitiesaimsreportdisability-adjustedlifeto 2021Methods:utilizeddataBurdenDiseaseGBDdatabaseanalyzeaged0-14RatescalculatedpopulationuncertaintyintervalsUIsData204countriesterritoriesstratifiedagesexlocationTrendsassessedusingJoinpointcomputepercentAPClog-transformedlinearcalculateestimatedaveragepercentageEAPCFindings:Globally5560373421-7560031977deaths144504-25285417418612710464-2232659226% -124%7251%35%44%30%08%89%27%raterose2518-0332819-0381260% -1462%4912%AmongfiveSociodemographicIndexEAPCslow-to-mid87%64%-210%22%09%-136%15%-157%RegionallyCentralAsiaexhibitedfastestEAPC = 276%218%-3levelIndianumberglobally68540416-100767Interpretation:relatedinitiallydecreasedalthoughincreasingtrendHoweverremainssignificantlow-low-middle-middle-SDIcomprehensiveunderstandingcrucialenhancingpreventioncontroleffortsFunding:researchfundedNatural2024GXNSFAA010420YouthMedicalUniversityGXMUYSF202404regional1990-2021:statisticalanalysisChildhoodIncidenceMortality

Similar Articles

Cited By